Deutsche Märkte öffnen in 6 Stunden 52 Minuten

RemeGen Co., Ltd. (REGMF)

OTC Markets OTCPK - OTC Markets OTCPK Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
2,04000,0000 (0,00%)
Börsenschluss: 09:39AM EDT

RemeGen Co., Ltd.

58 Middle Beijing Road
Yantai Development Zone Yantai Area of Shandong Pilot Free Trade
Yantai
China
86 53 56357 3672
https://www.remegen.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter3.615

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Weidong WangCo-Founder & Executive Chairman394,99kN/A1960
Dr. Jianmin FangCo-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director1,12MN/A1963
Mr. Shaojing TongCFO & Joint Company SecretaryN/AN/A1972
Dr. Ruyi He M.D.Chief Medical Officer, Member of Scientific Advisory Board & Executive Director1,06MN/A1962
Mr. Jian LinExecutive Director116,79kN/A1956
Mr. Kaisheng HuangChief Operating OfficerN/AN/AN/A
Dr. Marie ZhuChief Technical OfficerN/AN/AN/A
Dr. Zhulun WangChief Scientific OfficerN/AN/AN/A
Mr. Daniel R. RossChief Business OfficerN/AN/AN/A
Dr. Xiaoming Yang Ph.D.Chief Manufacturing OfficerN/AN/A1964
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

Corporate Governance

RemeGen Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.